IntelGenx Technologies Corp. - Product Pipeline Review - Q4 2010

Global Markets Direct, November 2010, Pages: 53

IntelGenx Technologies Corp. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “IntelGenx Technologies Corp. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- IntelGenx Technologies Corp. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of IntelGenx Technologies Corp. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of IntelGenx Technologies Corp. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the IntelGenx Technologies Corp.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate IntelGenx Technologies Corp.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of IntelGenx Technologies Corp. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the IntelGenx Technologies Corp.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with IntelGenx Technologies Corp..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of IntelGenx Technologies Corp. and identify potential opportunities in those areas.

List of Tables
List of Figures
IntelGenx Technologies Corp. Snapshot
IntelGenx Technologies Corp. Overview
Key Information
Key Facts
IntelGenx Technologies Corp. – Research and Development Overview
Key Therapeutic Areas
IntelGenx Technologies Corp. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
IntelGenx Technologies Corp. – Pipeline Products Glance
IntelGenx Technologies Corp. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
IntelGenx Technologies Corp. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
IntelGenx Technologies Corp.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
IntelGenx Technologies Corp. – Drug Profiles
CPI-300
Product Description
Mechanism of Action
R&D Progress
INT0001/2004
Product Description
Mechanism of Action
R&D Progress
INT0008/2007
Product Description
Mechanism of Action
R&D Progress
QuitPak
Product Description
Mechanism of Action
R&D Progress
Relivar
Product Description
Mechanism of Action
R&D Progress
CRES Pravastatin
Product Description
Mechanism of Action
R&D Progress
INT0011
Product Description
Mechanism of Action
R&D Progress
INT0014
Product Description
Mechanism of Action
R&D Progress
INT0015
Product Description
Mechanism of Action
R&D Progress
INT005
Product Description
Mechanism of Action
R&D Progress
IntelGenx Technologies Corp. – Pipeline Analysis
IntelGenx Technologies Corp. – Pipeline Products by Therapeutic Class
IntelGenx Technologies Corp. – Pipeline Products by Route of Administration
IntelGenx Technologies Corp. – Pipeline Products by Molecule Type
IntelGenx Technologies Corp. – Locations And Subsidiaries
Head Office
Recent Developments
Sep 02, 2010: IntelGenx Achieves Positive Bioequivalence Results For Erectile Dysfunction Film Product
Feb 08, 2010: IntelGenx Receives FDA Complete Response Letter For CPI-300
Jan 21, 2010: IntelGenx Receives Notice Of Allowance For CPI-300
Nov 17, 2009: IntelGenx Achieves Positive Bioequivalence Results With Novel Anti-Migraine Film
Jun 23, 2009: IntelGenx Corp. Announces FDA Acceptance For Filing Of NDA For CPI-300 Antidepressant
May 19, 2009: IntelGenx Corp. And Circ Pharma To Commence Phase 1 Proof-of-Concept Study Of CRES Pravastatin
Apr 14, 2009: Cannasat And IntelGenx Announce Positive Phase 1(b) Results Improved Buccal Tablet Outperforms Oral Dronabinol
May 03, 2007: IntelGenx Technologies Corp And Cary Pharmaceuticals Inc Announces Positive Results Of Pilot Pharmacokinetic (PK) Study On QuitPak (INT003/05).
Feb 07, 2007: IntelGenx Technologies Corp And Cary Pharmaceuticals Inc Announces Enrollment Of Phase I Pilot Study For QuitPak(INT003/05)
Nov 14, 2006: Cannasat Therapeutics And IntelGenx Enter Into A Collaborative Agreement To Develop Novel Cannabinoid-Based Products Based On Proprietary Drug Delivery Technologies
Financial Deals Landscape
IntelGenx Technologies Corp., Deals Volume Summary, 2004 to YTD 2010
IntelGenx Technologies Corp., Deals Summary By Region, 2004 to YTD 2010
IntelGenx Technologies Corp., Deals Summary, 2004 to YTD 2010
IntelGenx Technologies Corp. Detailed Deal Summary
Equity Offering
IntelGenx Technologies Completes Private Placement Of $0.09 Million
IntelGenx Technologies Completes Private Placement Of $0.13 Million
IntelGenx Technologies Completes Private Placement Of Special Warrants For $4 Million
IntelGenx Technologies Completes Private Placement Of $2.8 Million
IntelGenx Enters Into Co-Development Agreement With Circ Pharma
IntelGenx Enters Into Co-Development Agreement With Dava Pharmaceuticals
IntelGenx Enters Into Co-Development Agreement With Cary Pharmaceuticals
IntelGenx Enters Into Co-Development Agreement With Azur Pharma
IntelGenx Technologies Enters Into Co-Marketing Agreement
Cannasat Therapeutics Enters Into Co-Development Agreement With IntelGenx
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• eLEARNING - Global Strategic Business Report
• Aerospace and Defense Industry - Global Strategic Business Report
• Military Ground Robot Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018
• Distance Learning - Global Outlook
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Uncooled Infrared Imaging: Commercial & Military Applications 2012
• Special Service & Homeland Security Vehicle Manufacturing in North America
• First Responder, Border Patrol, Homeland Security, Law Enforcement, and Security Robots: Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• Education Services - Global Strategic Business Report